(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.98%) $83.03
(-1.16%) $1.619
(-0.43%) $2 337.00
(-0.78%) $27.32
(0.46%) $926.30
(-0.12%) $0.934
(-0.12%) $11.01
(-0.18%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics...
Stats | |
---|---|
Dagens volum | 2.22M |
Gjennomsnittsvolum | 2.84M |
Markedsverdi | 4.53B |
EPS | HKD0 ( 2023-08-23 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -19.58 |
ATR14 | HKD0.00400 (0.09%) |
Volum Korrelasjon
Alphamab Oncology Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Alphamab Oncology Korrelasjon - Valuta/Råvare
Alphamab Oncology Økonomi
Annual | 2023 |
Omsetning: | HKD218.77M |
Bruttogevinst: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2023 |
Omsetning: | HKD218.77M |
Bruttogevinst: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2022 |
Omsetning: | HKD166.85M |
Bruttogevinst: | HKD122.64M (73.50 %) |
EPS: | HKD-0.350 |
FY | 2021 |
Omsetning: | HKD146.02M |
Bruttogevinst: | HKD142.99M (97.93 %) |
EPS: | HKD-0.444 |
Financial Reports:
No articles found.
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.